Localized prostate cancer with intermediate- or high-risk features treated with combined external beam radiotherapy and iodine-125 seed brachytherapy

Brachytherapy

Volumn 9, Issue 4, 2010, Pages 307-312

  da Silva Franca, Carlos Antonio ^a   Vieira, Sérgio L ^a   Carvalho, Antônio Carlos P ^a   Bernabé, Antonio Jose S ^a   Penna, Antônio Belmiro Rodrigues C ^a  

^a Brazilian Institute of Oncology   (Brazil)

Author keywords

Brachytherapy; Iodine radioisotopes; Prostate specific antigen; Prostatic neoplasms; Radiotherapy; Recurrence

Indexed keywords

GONADORELIN AGONIST; IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RISK FACTORS;

EID: 77957354591     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2009.07.011     Document Type: Article

References (27)

1. National Cancer institute/Brasil. Estimative 2010: Incidence of cancer in Brasil. Rio de Janeiro, Brasil. Available at: Accessed August 04, 2010. http://www1.inca.gov.br/estimativa/2010/index.asp?link=conteudo_view.asp&ID=5.
2. Jani A.B., Feinstein J.M., Pasciak R., et al. Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer. Urology 2006, 67:1007-1011.
3. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005, 173:1562-1566.
4. Hoskin P.J., Venselaar J. Prostate brachytherapy in Europe: Growth, practice and guidelines. Radiother Oncol 2007, 83:1-2. on behalf of the BRAPHYQS and PROBATE groups of GEC ESTRO.
5. Nickers P., Thissen B., Jansen N., et al. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostate cancer: A dosimetric point of view. Radiother Oncol 2006, 78:47-52.
6. Blasko J.C., Grimm P.D., Sylvester J.E., et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000, 57:273-278.
7. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 61:32-43.
8. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
9. Joniau S., Poppel H.V. Localized prostate cancer: Can we better define who is at risk of unfavourable outcome?. BJU Int 2008, 101(Suppl. 2):5-10.
10. Bratt O. The urologist's guide to low dose-rate interstitial brachytherapy with permanent seed implants for localized prostate cancer. BJU Int 2006, 99:497-501.
11. Soto D.E., McLaughlin P.W. Combined permanent implant and external-beam radiation therapy for prostate cancer. Semin Radiat Oncol 2008, 18:23-34.
12. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommedations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999, 44:789-799.
13. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-year biochemical free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy: Seattle Experience. Int J Radiat Oncol Biol Phys 2007, 67:57-64.
14. Yu Y., Anderson L.L., Li Z., et al. Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No 64. Med Phys 1999, 26:2054-2076.
15. Salembier C., Lavagnini P., Nickers P., et al. Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007, 83:3-10.
16. Merrick G.S., Grimm P.D., Sylvester J.E., et al. Initial analysis of Pro-Qura: A multi-institutional database of prostate brachytherapy dosimetry. Brachytherapy 2007, 6:9-15.
17. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006, 64:965-974.
18. Stone N.N., Potters L., Davis B.J., et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009, 73:341-346.
19. Potters L., Fearn P., Kattan M.W. External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer. Brachytherapy 2002, 1:36-41.
20. Franca C.A.S., Vieira S.L., Bernabé A.J.S., et al. The seven-years preliminary results of brachytherapy with iodine-125 seeds for localized prostate cancer treated at a Brazilian single-center. Int Braz J Urol 2007, 33:752-763.
21. Khaksar S.J., Laing R.W., Henderson A., et al. Biochemical prostate-specific antigen relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy. BJU Int 2006, 98:1210-1215.
22. Critz F.A., Levinson K. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol 2004, 172:2232-2238.
23. Merrick G.S., Butler W.M., Wallner K.E., et al. Temporal effect of neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radiation. Brachytherapy 2004, 3:141-146.
24. Sylvester J.E., Blasko J.C., Grimm P.D., et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience. Int J Radiat Oncol Biol Phys 2003, 57:944-952.
25. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007, 67:327-333.
26. Ray M.E., Thames H.D., Levy L.B., et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006, 64:1140-1150.
27. Pollack A., Hanlon A.L., Horwitz E.M., et al. Prostate cancer radiotherapy dose response: An update of the fox chase experience. J Urol 2004, 171:1132-1136.